Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck.

Abstract

BACKGROUND Panitumumab has the potential to improve the therapeutic ratio of concurrent chemoradiotherapy for squamous cell carcinoma of the head and neck (SCCHN). PATIENTS AND METHODS This phase I dose-finding study investigated escalating doses of paclitaxel (Taxol) given concurrently with panitumumab, carboplatin and intensity-modulated radiotherapy… (More)
DOI: 10.1093/annonc/mdp477

Topics

4 Figures and Tables

Cite this paper

@article{Wirth2010PhaseID, title={Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck.}, author={Lori J. Wirth and Abby M Allen and Marshall Roy Posner and Robert I. Haddad and Yuesheng Li and Jonathan Clark and Paul M. Busse and Albert Yan Wo Chan and Laura A. Goguen and Charles M. Norris and Donald J Annino and Roy B. Tishler}, journal={Annals of oncology : official journal of the European Society for Medical Oncology}, year={2010}, volume={21 2}, pages={342-7} }